4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $488 | $207 | $180 | $300 |
| - Cash | $49 | $77 | $134 | $149 |
| + Debt | $22 | $23 | $24 | $25 |
| Enterprise Value | $461 | $153 | $70 | $176 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 500% | 7.1% | 1,300% | – |
| Gross Profit | -$47 | -$48 | $0 | -$2 |
| % Margin | -52,386.7% | -319,573.3% | 100% | -178,300% |
| EBITDA | -$56 | -$58 | -$52 | -$61 |
| % Margin | -61,794.4% | -388,600% | -370,478.6% | -6,103,800% |
| Net Income | -$57 | -$55 | -$48 | -$50 |
| % Margin | -63,195.6% | -364,386.7% | -342,657.1% | -4,967,100% |
| EPS Diluted | -1.01 | -0.98 | -0.86 | -0.9 |
| % Growth | -3.1% | -14% | 4.4% | – |
| Operating Cash Flow | -$46 | -$43 | -$48 | -$46 |
| Capital Expenditures | $0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$46 | -$43 | -$48 | -$47 |